We are so excited to have rescheduled
Sarah Forrester, PhD's AMPHIBIAN talk! Mark your calendars for Apr 17 2024 12-1 and register here: bit.ly/4412W55
Rich Jones (@[email protected]) Leslie Brick The Warren Alpert Medical School Brown University School of Public Health
How do we effectively measure disease modifying effects in progressive diseases like Alzheimer's?
We are going to need a lot more work rethinking along these lines for measuring the effects of #longevity interventions
nature.com/articles/d4158… highlights great work from medical…
A cop pulled me over after he saw me signing to my kid at the gas station, and he was confused why a deaf person was driving! He even called for back up though I had a valid driver’s license and insurance that clearly prove I am a licensed driver. He refused to write on paper to…
Leonardo Furlan Stephen John Senn Richard Riley (R²) The dichotomization of atherosclerosis progression in this paper is unforgivable, not to mention the use of stepwise regression that has been proven NOT to work. Million dollar data turned into 10 dollar mess. You’ll see a change in the journal w/the new editor JACC Journals
A workgroup dominated by industry wants to redefine #Alzheimer 's as an abnormal accumulation of amyloid, regardless of current or future cognitive function. This new definition raises a rarely asked question: Who gets to decide how to redefine a disease? agsjournals.onlinelibrary.wiley.com/doi/full/10.11…
Lectures from the 2023 ΨMCA (psymca.org) talks are posted on our YouTube (youtube.com/@psymca). Theme was Bayesian Psychometrics. Grateful for informative talks from Chun Wang, Roy Levy, James Uanhoro, David Fardo, and Paul Crane. Check it out. #ΨMCA2023
Some of you are looking for a video link to the full version of sunday's performance, not just a snippet and in the best quality possible. Good news! Recording Academy / GRAMMYs published it on their website. Click on the link in the first thread to watch it. Enjoy 🤩
#Grammys #tracychapman
Much news yesterday about Biogen abandoning Aducanumab (Aduhelm) which should have never received FDA approval, but do remember this is the extent of our knowledge regarding the disease progression benefits of the #Alzheimers drug they are now focusing on: lecanemab (Leqembi)
You only have the weekend left to complete & submit your NIDUS Delirium Network Pilot Grant LOI! Monday is the deadline. Don't miss out!
deliriumnetwork.org/pilots/
Sharon Inouye, MD John Devlin, PharmD, BCCCP, FCCP, MCCM Dale Needham, MD, PhD Donna Fick, PhD, GCNS-BC, FAAN Hebrew SeniorLife @elderlifeprog American Delirium Society AustralasianDelirium European Delirium
We are looking for a Scientist I to work on single-cell AI/ML models for Alzheimer's disease. The position is based out of Allen Institute and will work with Mariano Gabitto and me on genetics of mixed neuropathology. You can find more at tinyurl.com/2pnz6du7 Please RT.